Arcturus Outlines Inhaled mRNA CF Phase 2b Trial Plans, Secures FDA OTC Talks
Arcturus Therapeutics outlined plans for a Phase 2b trial of its inhaled mRNA cystic fibrosis therapy, aiming to refine dosing in CF patients. Company executives engaged FDA at a scientific summit to define the regulatory roadmap for an OTC cough-suppressant mRNA program.
1. Summit Presentation Overview
At a recent biotech summit, Arcturus Therapeutics presented updates on its inhaled mRNA cystic fibrosis candidate and an OTC cough mRNA program in discussions with FDA.
2. Inhaled mRNA CF Phase 2b Plan
Executives detailed a Phase 2b clinical study designed to optimize dose regimens and assess lung function improvements in cystic fibrosis patients, building on positive preclinical safety and efficacy results.
3. FDA Discussions for OTC Program
Arcturus held formal FDA meetings to outline regulatory requirements for an over-the-counter mRNA-based cough-suppressant product, seeking clarity on filing pathway, labeling and safety data expectations.